SOLICITATION NOTICE
B -- Genetic screening for interactions of wild type and mutant proteins
- Notice Date
- 7/25/2014
- Notice Type
- Presolicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NIH-NHLBI-CSB-(HG)-2014-174-DLM
- Archive Date
- 8/16/2014
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- INTRODUCTION: THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR A PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Institute of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) Office of Acquisition (OA) on behalf of the National Human Genome Research Institute, (NHGRI), intends to negotiate and award a purchase order on a noncompetitive sole source basis to Department of Molecular and Cellular Pharmacology, University of Miami, Miller School of Medicine, 1600 NW 10th Ave, RMSB 6085, Miami, FL 33136, to provide cutting edge genetic screening for interactions of wild type and mutant proteins identified in three individuals who have neurological abnormalities for NHGRI Undiagnosed Disease Program (UDP). BACKGROUND: The National Institutes of Health (NIH) mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The National Human Genome Research Institute (NHGRI) mission has expanded to encompass a broad range of studies aimed at understanding the structure and function of the human genome and its role in health and disease. NHGRI Undiagnosed Disease Program (UDP) is a trans-National Institute of Health (NIH) initiative that focuses on the most puzzling medical cases referred to the NIH Clinical Center in Bethesda, MD. Many medical specialties from other NIH research centers and institutes contribute the expertise needed to conduct the program, including endocrinology, immunology, oncology, dermatology, dentistry, cardiology and genetics, among the dozens of participating senior attending physicians. A longstanding medical condition that eludes diagnosis by a referring physician can be considered undiagnosed and may be of interest to this clinical research program. The University of Miami, Miller School of Medicine shall provide comprehensive and validated list of statistically significant interacting genes in S. pombe that potentially regulate the activity of nine genes associated with UDP patients. The Objective is to provide cutting edge genetic screening for interactions of wild type and mutant proteins identified in three individuals who have neurological abnormalities. Based on the previous contract results from University of Miami, Miller School of Medicine, the laboratory of Dr. Gennaro D'Urso will conduct nine S. pombe interactome screens that include 3 C19orf12 mutants, SPRK wild type and 3 mutants and UBE2V2 wild type and one mutant. The respective wild type and mutant open reading frames will be stably integrated into S. pombe to create query strains that express either wildtype or a variant (9 screens) of each gene under the control of the inducible nmt1 transcriptional promoter. Once integrated, will carefully analyze each strain for expression and localization of the protein and will monitor how overproduction of the wildtype or protein affects growth. Differences in phenotype between wild-type or mutant protein will provide evidence that the mutation alters a specific aspect of wild-type protein function. In some cases this might represent the first functional data regarding a specific gene variant. Once initial characterization is complete we will design genomics screens to interrogate the function of wild-type or mutant proteins. Period of Performance: Fully Funded for 18-Months Upon Award Contractor's Requirements : Specific Tasks: 1. The Contractor shall provide a phenotypic assessment of wild-type or mutant protein in S. pombe to provide evidence that the mutation alters a specific aspect of the wild-type protein function. 2. The Contractor shall provide a comprehensive and validated list of statistically significant interacting genes in S. pombe that potentially regulate the activity of the genes in question. 3. The Contractor shall provide bioinformatics analysis and interpretation of the genetic screen results using Metasearch of PubMed, searches of STRING, analysis of interactions through GEM.APP and related sites, and identification of phenologs. 4. The Contractor shall provide unique services specific to genes suspected of causing neurological disease to meet the program goals of the UDP. 5. The Contractor's turn-around-time for UDP to receive results will be 1.2 months once the initial validation is completed. 6. The Contractor shall supply electronic copies of all reports appropriate for deposition in the UDP process management system and for other collaborations. Desired Results/Functions/End Items : 1. Test results with qualified interpretations in a timely way given the requirements of the particular test. 2. Research collaborations will be conducted via Videoconferences, email communications, shared professional presentations, posters and publications. Grand Round presentations at the Contractor's location and the NIH Clinical Center may also occur. Technical Specifications/Standards/Methods: 1. The Contractor shall supply results with qualified interpretations in formats appropriate to the exome analysis pipeline and process management systems. Special Handling or Handling Requirements : 1. The Contractor shall provide result reports and record methods and materials as appropriate to the highest scientific standards. These materials, methods and results will be shared will agreed upon UDP collaborators. Government Responsibilities : The Government will provide to the Contractor : 1. The Government will not furnish any government property to the vendor. 2. The Government will provide plasmids of the wild type and mutant cDNAs for the genes to be investigated. 3. The Government will send all plasmids via Fed-Ex overnight to the Contractor for testing. 4. The Government will not furnish any facilities to be used by the vendor. The Government will be responsible for reviewing and approving reports and similar matters generated: 1. Results will be provided electronically to the UDP via secure email, the UDP ftp site or direct deposition into the UDP process management system. 2. Results will also be shared with UDP collaborators as defined mutually. Reporting Requirements and Deliverables: 1. The Government will receive all electronic results within 3.6 months of the Contractor receiving the plasmids. 2. The Government will receive additional reports for any test added-on after the Contractor receives the original specimen. REGULATORY AUTHORITY: This acquisition is conducted under the authority of the Federal Acquisition Regulations (FAR) Subpart 13.106-1(b) Soliciting from a single source, only one responsible source and no other supplies or services will satisfy agency requirements. ADDITIONAL INFORMATION : Industry Classification (NAICS) Code is 541712, Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology) and the Small Business Size Standard is 500. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001). The resultant Contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-74 (July 1, 2014). This requirement is under the SAT of $150,000.00. This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by August 1, 2014 and must reference synopsis number HHS-NIH-NHLBI-CSB-(HG)-2014-174-DLM, may be submitted to the National, Heart, Lung and Blood Institute, Office of Acquisition, COAC Services Branch, 6701 Rockledge Drive, Suite 6149, Bethesda, Maryland 20892-7902, Attention: Dorothy Maxwell. Response may be submitted electronically to maxwelld@mail.nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative. "All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NIH-NHLBI-CSB-(HG)-2014-174-DLM/listing.html)
- Place of Performance
- Address: NIH, 5635 Fishers Lane, Bethesda, Maryland, United States
- Record
- SN03438617-W 20140727/140725235105-06dd26d1635f279d72651f46f3dd7cf0 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |